Contact
searchSearch
HMP Global
Login

CD20-CD3 News

News
Pharmacology Model Predicts Treatment Benefits of Mosunetuzumab Among Patients With Non-Hodgkin Lymphoma
03/23/2023
Jordan Kadish
According to the phase 1/2 GO29781 trial, a quantitative systems pharmacology model predicted increased exposure to mosunetuzumab led to tumor size reduction among patients with non-Hodgkin lymphoma.
According to the phase 1/2 GO29781 trial, a quantitative systems pharmacology model predicted increased exposure to mosunetuzumab led to tumor size reduction among patients with non-Hodgkin lymphoma.
According to the phase 1/2...
03/23/2023
Oncology
News
Epcoritamab Yields High Overall and Complete Response Rates for Patients With R/R CD20+ LBCL
03/15/2023
Jordan Kadish
According to a phase 1/2 study, CD3-CD20 bispecific t-cell engaging antibody epcoritamab resulted in high overall response and complete response rates profile among patients with R/R CD20+ large b-cell lymphoma.
According to a phase 1/2 study, CD3-CD20 bispecific t-cell engaging antibody epcoritamab resulted in high overall response and complete response rates profile among patients with R/R CD20+ large b-cell lymphoma.
According to a phase 1/2 study,...
03/15/2023
Oncology
News
Subcutaneous Epcoritamab Combined With R-Dhax/C Yielded High ORR and CMR Rates in Patients With R/R DLBCL
02/10/2023
Jordan Kadish
An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.
An updated phase 1/2 dose escalation study found that a combination of subcutaneous epcoritamab and R-Dhax/C luxeptinib for patients with R/R diffuse b-cell lymphoma resulted in high ORR and CMR rates.
An updated phase 1/2 dose...
02/10/2023
Oncology
News
Odronextamab Demonstrates Promising Safety, Response in R/R Non-Hodgkin Lymphoma
11/17/2022
Gina Tomaine
CD20-CD3 bispecific antibody odronextamab showed a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent phase 1 study.
CD20-CD3 bispecific antibody odronextamab showed a manageable safety profile and encouraging preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, according to a recent phase 1 study.
CD20-CD3 bispecific antibody...
11/17/2022
Oncology
News
Mosunetuzumab Demonstrates Safety, Efficacy in Patients With Relapsed/Refractory Follicular Lymphoma
11/17/2022
Gina Tomaine
CD20-CD3 bispecific antibody mosunetuzumab demonstrated a favorable safety profile and induced high rates of complete remission in patients with relapsed/refractory follicular lymphoma, according to a phase 2 study.
CD20-CD3 bispecific antibody mosunetuzumab demonstrated a favorable safety profile and induced high rates of complete remission in patients with relapsed/refractory follicular lymphoma, according to a phase 2 study.
CD20-CD3 bispecific antibody...
11/17/2022
Oncology
News
CD20-CD3 Bispecific Antibody Shows High Efficacy in Relapsed/Refractory Follicular Lymphoma
03/08/2022
A pivotal expansion cohort of mosunetuzumab showed high potency for R/R FL with 3 out of 4 patients experiencing an ORR of 78.9%.
A pivotal expansion cohort of mosunetuzumab showed high potency for R/R FL with 3 out of 4 patients experiencing an ORR of 78.9%.
A pivotal expansion cohort of...
03/08/2022
Oncology
News
CRS Tool Predicts Risk Events in Patients With R/R NHL Receiving Glofitamab
02/07/2022
A management tool for grade ≥ 2 CRS events was developed to enable stratification in patients with R/R NHL who receive glofitamab, presented at ASH 2021.
A management tool for grade ≥ 2 CRS events was developed to enable stratification in patients with R/R NHL who receive glofitamab, presented at ASH 2021.
A management tool for grade ≥ 2...
02/07/2022
Oncology
News
IGM-2323 Shows Favorable Safety Profile With Advanced B-Cell Malignancies
02/01/2022
IGM-2323, an anti-CD20 x anti-CD3 IgM T-cell engager, achieves complete responses and a favorable safety profile in patients with advanced B-cell malignancies, presented at ASH 2021.
IGM-2323, an anti-CD20 x anti-CD3 IgM T-cell engager, achieves complete responses and a favorable safety profile in patients with advanced B-cell malignancies, presented at ASH 2021.
IGM-2323, an anti-CD20 x...
02/01/2022
Oncology
News
CT-P10 and Rituximab Yield Favorable Outcomes in Patients With FL
10/04/2021
Findings from a randomized phase 3 study showed the efficacy and safety of CT-P10 or rituximab in patients with untreated advanced FL.
Findings from a randomized phase 3 study showed the efficacy and safety of CT-P10 or rituximab in patients with untreated advanced FL.
Findings from a randomized phase...
10/04/2021
Oncology
Interview
Case Study Shows Success of Ibrutinib for CLL/SLL After Allo-HSCT
08/11/2021
Masatoshi Sakurai, MD, PhD, discusses the successful use of ibrutinib in a patient with CLL/SLL who had CNS relapse approximately 10 years after allo-HSCT.
Masatoshi Sakurai, MD, PhD, discusses the successful use of ibrutinib in a patient with CLL/SLL who had CNS relapse approximately 10 years after allo-HSCT.
Masatoshi Sakurai, MD, PhD,...
08/11/2021
Oncology

Recent News

News
Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/05/2026
Emily Estrada
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study...
06/05/2026
Oncology
News
Fedratinib Demonstrates Potential Clinical Promise in Patients With Proliferative MDS/MPNs and Chronic Neutrophilic Leukemia
06/05/2026
Emily Estrada
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study...
06/05/2026
Oncology
News
Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma
06/05/2026
Emily Estrada
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study...
06/05/2026
Oncology
News
ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma
06/05/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial...
06/05/2026
Oncology
News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology
News
Ropeginterferon Shows Efficacy Across Treatment Lines and Mutation Subtypes in Essential Thrombocythemia
06/01/2026
Stephanie Holland
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated analysis of the SURPASS-ET and EXCEED-ET studies demonstrated consistent hematologic and molecular efficacy with ropeginterferon alfa-2b across diverse patient populations with essential thrombocythemia.
Results from an integrated...
06/01/2026
Oncology
News
Asandeutertinib Demonstrates Superior Intracranial Efficacy in EGFR-Mutated NSCLC
05/31/2026
Emily Estrada
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA...
05/31/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
HARMONi-6 Trial Positions Ivonescimab Plus Chemotherapy as New First-Line Standard of Care in Squamous NSCLC
05/31/2026
Emily Estrada
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial position ivonescimab plus chemotherapy as a new first-line standard-of-care for patients with squamous non-small cell lung cancer.
Results from the HARMONi-6 trial...
05/31/2026
Oncology
News
Metronomic Chemo-Immunotherapy Improves Survival in Metastatic Head and Neck Cancer
05/31/2026
Stephanie Holland
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial showed that triple oral metronomic chemotherapy combined with ultra-low-dose nivolumab demonstrates clinical promise among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results from a phase 3 trial...
05/31/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use